EMERGE ARK GENOMICS & BIOTECH ETF

Ticker: EAGB

Emerge goes live with Max Friedrich (Fintech Analyst, ARK Invest) on March 3rd, 3PM ET

Investment Objectives

EAGB is an actively managed exchange-traded fund (ETF) that seeks to achieve long-term growth of capital by investing primarily, under normal circumstances, in the global equity securities of companies that are, or are expected to be, focused on extending and enhancing the quality of human and other life through technological and scientific developments, improvements and advancements in biotech and genomics

Profile of an Innovator : Portfolio Manager

Catherine Wood founded ARK Investment Management in 2014. She spent the previous 12 years at Alliance Bernstein as Chief Investment Officer of Global Thematic Strategies that had over US$5 billion in assets under management. Before AllianceBernstein, she worked for 18 years with Jennison Associates as Chief Economist, Equity Research Analyst, Portfolio Manager and Director. Catherine started her career in Los Angeles at the Capital Group as an Assistant Economist.

Why Invest?

Exposure to Innovation: Aims to achieve thematic multi-capitalization exposure to innovation across sectors. ARK believes the securities held in EARK present the best risk-reward opportunities from ARK’s innovation-based themes.

Growth Potential: Aims to capture long-term growth with low correlation of relative returns to traditional growth strategies and negative correlation to value strategies.

Tool for Diversification: Active stock selection results in little overlap with traditional indices. EAGB can be a complement to traditional value/growth strategies.

Grounded in Research: Combines top-down and bottom-up research in its portfolio management to identify innovative companies and convergence across markets.

Cost Effective: Provides a lower-cost alternative to mutual funds with true active management in an ETF that invests in rapidly moving themes.

Top 10 Holdings

As at January 31, 2021

Teladoc Health Inc7.94%
Twist Bioscience Corporation5.58%
Pacific Biosciences of California Inc.5.42%
EXACT Sciences Corporation 4.01%
Regeneron Pharmaceuticals Inc3.83%
Roche Holdings Ltd AG3.67%
CareDx Inc 3.66%
CRISPR Therapeutics AG3.49%
Vertex Pharmaceuticals Inc3.44%
Fate Therapeutics Inc3.14%
Click Here to Download EAGB Full Holdings Report as at January 31, 2021
Fund Facts

EAGB NAV (As at February 23 , 2021):
$26.61
EAGB.U NAV (As at February 23 , 2021):
$21.12


CUSIP CAD Series: 291004109
CUSIP USD Series: 291004208
TICKER: EAGB
INCEPTION DATE: 7.29.2019
EXCHANGE: NEO Stock Exchange
MANAGEMENT FEE: 0.80%
CURRENCY: CAD/USD
SUB-ADVISORS: ARK Investment Management LLC

Fund Characteristics

As at January 31, 2021

  • Americas 83.8%
  • Europe 11.7%
  • Middle East 1.1%
  • Asia 3.1%
Sector Allocation

As at January 31, 2021

  • Health Care 96.1%
  • Information Technology 1.8%
  • Communication Services 1.4%
  • Consumer Discretionary 0.1%
  • Financials 0.3%